NCT04640272View on ClinicalTrials.gov

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

November 19, 2021

Study Completion Date

December 22, 2021

Conditions

Exudative Age-related Macular Degeneration

Interventions

DRUG

RBM-007

Intravitreal injection

Trial Locations (6)

46290

Raj K. Maturi, M.D., P.C., Indianapolis

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute, McAllen

85053

Retinal Research Institute, LLC, Phoenix

94704

Bay Area Retina Associates, Walnut Creek

95841

Retinal Medical Consultants Group, Sacramento

All Listed Sponsors

lead

Ribomic USA Inc

INDUSTRY

NCT04640272 - A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter